Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Autor Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Vydáno 2015-08-01

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.

Autor Bajetta, E., Zilembo, N., Buzzoni, R., Noberasco, C., Di Leo, A., Bartoli, C., Merson, M., Sacchini, V., Moglia, D., Celio, L.
Vydáno 1994

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Autor Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchi, A.
Vydáno 1995

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Autor Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM
Vydáno 2014-05-01